

Security and effectiveness assessment of locking systems in ventriculostomy for traumatic brain injury

Submission date 02/01/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/04/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 03/04/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study focuses on traumatic brain injuries (TBI), a condition that can cause severe intracranial pressure and life-threatening complications. This study aims to compare the effectiveness and safety of a standard intervention called ventriculostomy for managing increased intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI). Elevated ICP is a critical condition that can result in brain damage or death if not treated promptly. The goal is to reduce complications like catheter displacement and improve outcomes for patients with intracranial compartment syndrome (ICCS).

Who can participate?

Adults aged 18 to 70 years old with confirmed ICCS caused by TBI

What does the study involve?

The intervention will be performed in a traditional standard way or with an additional device called a catheter locking system. The first approach, standard ventriculostomy, involves placing a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF), thereby reducing ICP. The second approach incorporates the same catheter plus a catheter-locking device designed to secure the catheter in place, potentially reducing complications such as catheter displacement and the need for additional surgeries. Participants in this study will undergo either standard ventriculostomy or ventriculostomy with the locking device. Their progress will be observed during their hospital stay until the catheter is taken out (regularly on days 5th to 7th after the initial surgery) and assessed over the course of 1 year through structured telephone follow-ups. The main outcomes include functional recovery and the rate of complications such as operative site infections, catheter displacement, and/or reinterventions. By comparing these two methods, the study seeks to determine whether the locking device improves outcomes for TBI patients while maintaining or enhancing the safety and reliability of the procedure.

What are the possible benefits and risks of participating?

Participants may benefit from a more stable and effective method of reducing ICP, especially if they are assigned to the locking device group. The study provides access to expert surgical care

and close monitoring throughout the recovery process. Contributions to this research could lead to improved treatment protocols for future TBI patients worldwide.

Both procedures carry inherent surgical risks, including infection, bleeding, or complications related to catheter placement and not to the study per se. Because the indications for any of the two interventions will be the same for the original procedure at the discretion of the neurosurgeon on call. Participants will be required to attend follow-up assessments, which may involve some time and effort. All procedures will be performed by experienced neurosurgeons following established safety protocols. Participants will be closely monitored, and any complications will be promptly addressed. This study represents an important step toward advancing surgical techniques for managing severe TBI and improving the quality of care for patients worldwide.

Where is the study run from?

The study is conducted across multiple international centers, including countries with both high- and low-resource settings.

When is the study starting, and how long is it expected to run for?

December 2024 to February 2027

Who is funding the study?

NTPlast S.r.l. (Italy)

Who is the main contact?

Dr Andrés M Rubiano MD, PhD(c), FACS, IFAANS, rubianoam@outlook.com, direccion@meditechhubcol.org

Study website

<https://seals-tbi-study.com/>

Contact information

Type(s)

Principal Investigator

Contact name

Dr Andrés M Rubiano

ORCID ID

<http://orcid.org/0000-0001-8931-3254>

Contact details

Calle 7A # 44-103

Cali

Colombia

760036

+ 57 3006154775

rubianoam@outlook.com

Type(s)

Scientific

Contact name

Ms Wendy Gonzalez

ORCID ID

<http://orcid.org/0009-0000-7106-3568>

Contact details

Calle 7A # 44-103

Cali

Colombia

760036

+57 310 537 4949

gonzalez.wendy.meditechf@outlook.com

Type(s)

Public

Contact name

Mr Santiago Cardona

Contact details

Calle 7A # 44-103

cali

Colombia

760036

+ 57 324 59 31186

cardona.santiago.meditechf@outlook.com

Type(s)

Scientific

Contact name

Ms Wendy Gonzalez

Contact details

Calle 7A # 44-103

Cali

Colombia

760036

+57 310 537 4949

proyectos@meditechhubcol.org

Type(s)

Principal Investigator

Contact name

Dr Andrés M Rubiano

Contact details

Calle 7a #44-103

Cali

Colombia
760036
+57 313 251 4132
direccion@meditechhubcol.org

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Comparative effectiveness study on catheter locking device versus standard ventriculostomy for surgical management of traumatic brain injury patients with intracranial compartment syndrome

Acronym

SEALS-TBI

Study objectives

The objective of this study is to determine the outcomes of standard ventriculostomy versus the use of a locking system for the ventricular catheter in the surgical management of patients with TBI and intracranial compartment syndrome.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 31/01/2025, Meditech Ethics and Research Committee (Calle 7A # 44-103, Cali, 760036, Colombia; +57 602 372 06 72; comitedeeticainvestigacion@meditechhubcol.org), ref: CEIM-2024-12-101

Study design

Prospective multicentric observational comparative-effectiveness study

Primary study design

Observational

Secondary study design

Comparative-effectiveness study

Study setting(s)

Hospital, Medical and other records, Telephone

Study type(s)

Efficacy

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Intracranial compartment syndrome in traumatic brain injury patients

Interventions

The study will include patients with traumatic brain injury and intracranial compartment syndrome managed either by standard ventriculostomy or ventriculostomy plus a locking system device.

Methodological Description:

Enrollment:

Participants are screened upon admission to the emergency room after experiencing a traumatic brain injury (TBI). Eligibility is determined using clinical and imaging criteria, including abnormal brain CT scans and evidence of intracranial compartment syndrome (ICCS), which is defined as a primary intracranial injury generating loss of intracranial compliance and generating risk for brain tissue hypoxia and/or hypoperfusion. Informed consent is obtained from participants or their legal representatives as many of these patients can arrive with a low level of consciousness due to the TBI.

Surgical Intervention:

Participants are assigned to one of two groups:

Standard Ventriculostomy: Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is a common procedure performed in this type of patient. Do not include a novel technique.

Ventriculostomy with a Locking Device: This intervention is the same procedure, but it will be performed with an additional approved device, a locking system that secures the catheter in place, reducing the risk of displacement and associated complications.

The system requires internal approval by regulatory entities in each of the participant countries. Most of them already have approval and the others are in an internal approval process.

Countries cannot start collecting data until they have the internal government approval for the device distribution by internal medical suppliers.

Follow-Up and Monitoring:

Observation During Hospitalization:

Patients with this type of procedure always go for postoperative management to intensive care units (ICUs), independent of the study. Follow-up is performed by ICU personnel and includes systemic multimonitoring and they evaluate catheter functionality, and complications such as infections or displacement. They regularly require head imaging control with CT not specifically associated with the study (is an observational CEI study). The data collectors of the study will be collecting physiological variables and descriptions of catheter integrity on a daily basis from the clinical records of the ICU. The follow-up will include the first two weeks after surgery, but in

general, these types of catheters do not remain in place for more than 8 days. Regularly they are taken out by the neurosurgery service between 5 to 7 days after insertion. Data monitoring will be performed by the central research team in permanent contact with the local investigators.

Long-Term Follow-Up:

Data will be collected from the medical record until discharge or transfer of the patient and by telephone interview at 3, 6, and 12 months after the admission. The telephone follow-up will include the application of the Glasgow Outcome Scale - Extended version (GOSE), and evaluations of functional recovery.

Duration:

Total Observation: Participants will be observed continuously during their hospital stay.

Data Collection and Sources:

Data will be collected from the medical records.

Demographic and Clinical Data: Includes age, sex, baseline health, and mechanism of trauma.

Surgical Outcomes: Will include the catheter placement, patency and complications if any reported in the medical record or observed inside the ICU.

Functional Outcomes: Evaluated from the medical records and GOSE scores.

Data Sources: Data will be collected from medical records, direct observations, and after discharge by telephone interviews conducted by trained personnel.

Intervention Type

Procedure/Surgery

Primary outcome measure

Functional outcomes measured using the Glasgow Outcome Scale Extended at discharge, 3 months, 6 months, and 12 months after surgery

Secondary outcome measures

1. Control of intracranial compartment syndrome measured using ICP waveform via invasive and non-invasive devices and/or non-invasive neuromonitoring techniques (digital pupillometry, optic nerve sheath diameter ultrasonographic measurement and transcranial Doppler) daily during ICU admission
2. Frequency and type of neurosurgical interventions required measured using data collected from medical records when possible and telephone follow-up as an alternative until the end of the follow-up at 12 months after the initial surgery
3. Medical and surgical treatment intensity measured from the ICU according to the categories of stratified management of intracranial pressure proposed in the study methodology that is based on international guidelines for the management of intracranial hypertension at discharge
4. Surgical site complications measured using data collected from medical records when possible and telephone follow-up as an alternative until the end of the follow-up at 12 months after the initial surgery
5. ICU and in-hospital length of stay measured using data collected from medical records at hospital discharge

Overall study start date

27/12/2024

Completion date

28/02/2027

Eligibility

Key inclusion criteria

1. TBI patients arriving at the emergency room in the first 24 hours following trauma
2. Abnormal CT scan, with a primary injury including any epidural, intracerebral or subdural collection with a midline shift >3 mm and any basal cistern compression with at least 2 abnormal findings in the initial evaluation at the emergency room including optic nerve ultrasound > 6 mm on the eye at the same side of the CT's primary injury or and/or an abnormal pupillometry with a reduced MCV in the pupil of the same side of the CT's primary injury, or/and a TCD with PI > 1.3 and/or MCA-DV < 20 cm/seg on the same side of the CT's primary injury or/and a P2>P1 waveform pattern in the same side of the CT's primary injury.
3. Age 18 to 70 years old
4. Patients with or without polytrauma with survival expectancy >24 hours
5. Cranial decompression or cranial expansion surgical procedures less than 24 hours from the trauma

Participant type(s)

Patient

Age group

Mixed

Lower age limit

18 Years

Upper age limit

70 Years

Sex

Both

Target number of participants

292

Key exclusion criteria

1. TBI patients arriving at the emergency room after 24 hours following trauma
2. Normal CT scan at the emergency room
3. Abnormal CT scan at the emergency room with any primary injury and a midline shift less than 3mm or without basal cistern compression and with normal values in at least two different modalities of assessing ICCS (pupillometry, optic nerve sheath ultrasound, transcranial Doppler and/or non-invasive ICP waveform analyzer
4. Age less than 18 or more than 70 years old
5. Polytrauma or massive brain injury with survival expectancy <24 hours
6. Cranial decompression or cranial expansion surgical procedures performed >24 hours after the trauma

Date of first enrolment

30/04/2025

Date of final enrolment

01/02/2027

Locations

Countries of recruitment

Bolivia

Brazil

Cambodia

Cameroon

Chile

China

Colombia

Dominican Republic

Ecuador

Egypt

England

Guatemala

India

Italy

Mexico

Nigeria

Paraguay

Peru

Philippines

Rwanda

Serbia

South Africa

Spain

Tanzania

Thailand

United Kingdom

United States of America

Venezuela

Study participating centre

Hospital Universitario del Valle Evaristo García

Calle 5 ·#36-08

Cali

Colombia

760042

Study participating centre

Hospital de Kennedy

Carrera 78 #41A-85 Sur

Bogota

Colombia

110871

Study participating centre

Clínica Santa Gracia

Calle 14 Norte #9-15

Popayan

Colombia

190003

Study participating centre

Clinica Abel Gonzalez

Avenida Independencia #101

Santo Domingo

Dominican Republic

10109

Study participating centre

Hospital de Emergencia Jose Casimiro Ulloa

Av. Roosevelt 6355

Lima
Peru
150122

Study participating centre
Hospital Nacional Daniel Alcides Carrion
Av. Guardia Chalaca 2176
Callao
Peru
07001

Study participating centre
Hospital Belen de Trujillo
Jiron Bolivar 350
Trujillo
Peru
13001

Study participating centre
Hospital Miguel Pérez Carreño
Av. San Martín, a la altura de Maternidad
Caracas
Venezuela
1020

Study participating centre
Hospital Central de Maracay
Av. Las Delicias, Maracay
Maracay
Venezuela
2101

Study participating centre
Hospital Enrique Tejera
Av. Lisandro Alvarado
Valencia
Venezuela
2001

Study participating centre
Hospital das Clínicas da FMUSP
Av. Dr. Enéas de Carvalho Aguiar, 255
São Paulo
Brazil
05403-900

Study participating centre
Fundação Hospitalar Getúlio Vargas
Avenida Apurinã, número 4, en el barrio Praça 14 de Janeiro
Manaus
Brazil
69020

Study participating centre
Hospital Obrero No. 1
Calle Lucas Jaimes 76
La Paz
Bolivia
0000

Study participating centre
Hospital Regional San Juan de Dios
Calle Santa Cruz
Tarija
Bolivia
0000

Study participating centre
Hospital Clínico Mutual de Seguridad
Av. Libertador Bernardo O'Higgins
Santiago de Chile
Chile
4848

Study participating centre
Hospital Puerto Montt
Los Aromos 65, Puerto Montt
Los Lagos
Chile
5480000

Study participating centre
Hospital General San Juan de Dios
1ra Avenida "A" 10-50
Ciudad de Guatemala
Guatemala
01010

Study participating centre
Hospital Roosevelt
Calzada Roosevelt
Ciudad de Guatemala
Guatemala
01011

Study participating centre
Hospital del Trauma Prof. Dr. Manuel Giagni
Av Gral Máximo Santos
Asunción
Paraguay
1500

Study participating centre
Hospital de Especialidades Eugenio Espejo
Av. Gran Colombia
Quito
Ecuador
170403

Study participating centre
Hospital General Monte Sinai
Av. Gran Colombia
Quito
Ecuador
170515

Study participating centre
Hospital General Docente Ambato
Av. Pasteur y Unidad Nacional

Ambato
Ecuador
180104

Study participating centre
Hospital General Rodríguez Zambrano
Barrio Sta. Martha Calle 12 V-A San Mateo
Manta
Ecuador
130213

Study participating centre
University College Hospital
Queen Elizabeth Road, Ibadan, Oyo State
Ibadan
Nigeria
200212

Study participating centre
Rwanda Military Hospital
Street KK739ST, Kanombe, Distrito de Kicukiro
Kigali
Rwanda
250

Study participating centre
Garoua Regional Teaching Hospital
Boulevard Docteur Jamot, Garoua, Región Norte
Garoua
Cameroon
237

Study participating centre
El Qasr El Ainy Hospital
27 Nafezet Sheem El Shafaey St, Kasr Al Ainy
Cairo
Egypt
11562

Study participating centre
Muhimbili Orthopaedic Hospital
Kalenga Street, West Upanga,
Dar es Salaam
Tanzania
141111

Study participating centre
Bicol Regional Hospital and Medical Center
Rizal St. 4501
Daraga
Philippines
4501

Study participating centre
Techo Santepheap National Hospital
JRC6+JR Win Win Blvd, Phnom
Penh
Cambodia
12000

Study participating centre
Khon Kaen Hospital
54 Sri Chant Rd, Nai Mueang, Mueang Khon Kaen District
Khon Kaen
Thailand
40000

Study participating centre
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Viale del Policlinico, 155, 00161 Roma RM, Italia
Rome
Italy
0649971

Study participating centre
Neurosurgical Clinic University Clinical Centre of Serbia
Dr Koste Todorovića 4, Beograd
Belgrado
Serbia
11000

Study participating centre
Centro Diagnóstico de Especialistas Ltda
Calle 13 No. 11-75, Riohacha, Guajira
Riohacha
Colombia
440001

Sponsor information

Organisation
Meditech Foundation

Sponsor details
Calle 7A # 44-103
Cali
Colombia
760036
+57 317 392 62 09
asistenciafundacionmeditech@gmail.com

Sponsor type
Research organisation

Website
<https://www.meditechfoundationglobal.org/>

Funder(s)

Funder type
Industry

Funder Name
NTPlast

Results and Publications

Publication and dissemination plan
Planned publication in a peer-reviewed journal

Intention to publish date

28/02/2028

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from MS Dr Wendy Gonzalez (gonzalez.wendy.meditectf@outlook.com). Participant-level data (IPD) collected during the study will be securely stored in a private repository managed using institutional REDCap software based on our internal server. The server and the repository are not publicly accessible, ensuring the confidentiality and protection of participant information. The data will be organized and maintained according to strict data management protocols, including anonymization procedures to remove personally identifiable information. Access to the repository will be limited to authorized personnel involved in the study, and all data usage will comply with ethical and legal standards. Additional details about data sharing, including the timing of availability and any restrictions, will be included in the study record once finalized. Databases for the study will be available upon request to any of our standard channels of communication.

IPD sharing plan summary

Stored in non-publicly available repository, Available on request